A new generation of lupus investigators
History
GLADEL has more than 20 years of sustained work with a significant number of contributions to the field of lupus, not only in the differential role that race/ethnicity plays in its course and outcome but also in several other studies including the beneficial effects of using antimalarials in lupus patients and the development of consensus guidelines for the treatment of lupus in our region.
Objective
A new generation of “Lupus Investigators” throughout Latin America launched a novel study that aim to identify subgroups of patients with SLE, based on demographic and clinical profile, serum and urinary biomarkers and transcriptome studies using blood and tissue RNA to identify potential transcriptional signatures.
This study is supported and funded by Janssen Research & Development, LLC.
GLADEL 2.0 Cohort. Study design.
Latin-American registry.
Research Centers
ARGENTINA
BRASIL
CHILE
COLOMBIA
ECUADOR
MÉXICO
PARAGUAY
PERÚ
REPUBLICA DOMINICANA
URUGUAY
History
GLADEL has more than 20 years of sustained work with a significant number of contributions to the field of lupus, not only in the differential role that race/ethnicity plays in its course and outcome but also in several other studies including the beneficial effects of using antimalarials in lupus patients and the development of consensus guidelines for the treatment of lupus in our region.
Objective
A new generation of “Lupus Investigators” throughout Latin America launched a novel study that aim to identify subgroups of patients with SLE, based on demographic and clinical profile, serum and urinary biomarkers and transcriptome studies using blood and tissue RNA to identify potential transcriptional signatures.
This study is supported and funded by Janssen Research & Development, LLC.
GLADEL 2.0 Cohort. Study design.
Latin-American registry.
Research Centers
ARGENTINA
BRASIL
CHILE
COLOMBIA
ECUADOR
MÉXICO
PARAGUAY
PERÚ
REPUBLICA DOMINICANA
URUGUAY